Spatial predictions of Rhodesian human African trypanosomiasis
(sleeping sickness) prevalence in Kaberamaido and Dokolo, two newly affected districts of Uganda.
A combination of nifurtimox and eflornithine has shown promising results in the treatment of second stage of African trypanosomiasis
(18), but its use is marred by dangerous side-effects.
There are two types of African Sleeping Sickness/ Human African Trypanosomiasis
(HAT), which cause distinct clinical features.
Cluster of African trypanosomiasis
in travellers to Tanzanian national parks.
The work to be presented represents basic research designed to identify potential drug therapy targets for African trypanosomiasis
Specifically, East African trypanosomiasis
is caused by T.
The development of fexinidazole for the treatment of African trypanosomiasis
, commonly known as "sleeping sickness", by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, Nerviano, Italy, a business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of DNDi's Success Stories of the Year.
has announced that the FDA has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis
(HAT), also known as African sleeping sickness.
Diagnosis of African trypanosomiasis
was made on a Giemsa-stained blood smear (Fig.
It transmits sleeping sickness - human African trypanosomiasis
It causes sleeping sickness or human African Trypanosomiasis
, which kills 60,000 people a year.
This buffering effect conferred by biodiversity may also apply to other human infectious diseases such as West Nile encephalitis, cutaneous and visceral leishmaniasis, African trypanosomiasis
, and Chagas disease (Ostfeld and Keesing 2000b).